Award Number: DAMD17-02-1-0308

TITLE: Targeting of an Anti-Metastatic and Anti-Angiogenic Compound to Breast Tumors

PRINCIPAL INVESTIGATOR: David Peters

CONTRACTING ORGANIZATION: The Burnham Institute La Jolla, CA 92037

**REPORT DATE: June 2005** 

# 20060307 063

AD

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

l III III III	EPORT DO	CUMENTATION	N PAGE		Form Approved OMB No. 0704-0188
ublic reporting burden for this	collection of information is earning the collection of the collect	stimated to average 1 hour per response f information. Send comments regar	nse, including the time for revier rding this burden estimate or an	wing instructions, search	hing existing data sources, gathering and maintainin lection of information, including succestions for redu
is burden to Department of L	efense, Washington Headqua	arters Services, Directorate for Inform	nation Operations and Reports ( shall be subject to any penalty f	(0704-0188), 1215 Jeffer for failing to comply with	rson Davis Highway, Suite 1204, Arlington, VA 222 a collection of information if it does not display a cu
alid OMB control number. PI	EASE DO NOT RETURN YO	UR FORM TO THE ABOVE ADDR	ESS.	130	ATES COVERED
1-06-2005		Annual Summarv	na na S <b>e</b> ria atana. Atagina di sanatana a	15	May 2004 –15 May 2005
TITLE AND SUBTIT	LE			5a.	CONTRACT NUMBER
argeting of an Ar	ti-Metastatic and	Anti-Angiogenic Com	oound to Breast Tu	mors	
			. *	5b.	GRANT NUMBER
				5c.	PROGRAM ELEMENT NUMBER
. AUTHOR(S)				5d.	PROJECT NUMBER
David Peters		a da series de la companya de la co La companya de la comp	· · · ·	56,	
				5f.\	
(	전신 - 고려 지출은 고려있. 			<b>·</b> • • • •	
PERFORMING OR	JANIZATION NAME	S) AND ADDRESS(ES)		8. P	ERFORMING ORGANIZATION REPO
ha Dumbana Irat	it ita			C N	IUMBER
ne burnnam inst					
a Jona, 0/1 3200	, <b>1</b>		· .		
			· · · ·		
	د. او موجد و بار مدینه آن که هم او ا				
. SPONSORING / MO	DNITORING AGENCY	NAME(S) AND ADDRESS	S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S
IC Arrow Modios					
J.S. Anny Medica	I Research and N	lateriel Command			
Fort Detrick, Mary	I Research and N land 21702-5012	lateriel Command		11	SPONSOR/MONITOR'S REPORT
Fort Detrick, Mary	a Research and N land 21702-5012	lateriel Command		, 11.	SPONSOR/MONITOR'S REPORT NUMBER(S)
Fort Detrick, Mary	al Research and N land 21702-5012	lateriel Command		11.	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION /	N Research and N land 21702-5012	lateriel Command			SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION /	al Research and N land 21702-5012 AVAILABILITY STATE ic Release; Distril	lateriel Command EMENT bution Unlimited		11.	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION 7	al Research and N land 21702-5012 AVAILABILITY STATE lic Release; Distril	lateriel Command EMENT bution Unlimited		, <b>11.</b>	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION /	al Research and N land 21702-5012 AVAILABILITY STATI lic Release; Distril	lateriel Command EMENT bution Unlimited		<b>11.</b>	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION / Approved for Pub	N Research and N land 21702-5012 AVAILABILITY STATI lic Release; Distril	Iateriel Command		11.	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION / Approved for Pub	N Research and N land 21702-5012 AVAILABILITY STATI lic Release; Distril	Iateriel Command		<b>11.</b>	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION / Approved for Pub	N Research and N land 21702-5012 AVAILABILITY STATI lic Release; Distril	lateriel Command		11.	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION / Approved for Pub	N Research and N land 21702-5012 AVAILABILITY STATI lic Release; Distril	Iateriel Command		11.	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION / Approved for Pub	AVAILABILITY STATI Ic Release; Distril	Interiel Command	ogenesis tumor gro	11.	SPONSOR/MONITOR'S REPORT NUMBER(S)
2. DISTRIBUTION / Approved for Pub	AVAILABILITY STATI	Iateriel Command EMENT bution Unlimited in which inhibits angic anti-angiogenic and a	ogenesis, tumor gro nti-tumor effects an	pwth, and meta	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 14. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe	AVAILABILITY STATI Ic Release; Distril Y NOTES	EMENT bution Unlimited in which inhibits angle anti-angiogenic and a endence on circulating	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir	owth, and meta nd has been for n to be active <i>i</i>	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe	AVAILABILITY STATI AVAILABILITY STATI IIC Release; Distril Y NOTES Y NOTES	EMENT bution Unlimited in which inhibits anglo anti-angiogenic and a endence on circulating ic blood vessels also r	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir equires the presen	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI
2. DISTRIBUTION 7 Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe anastellin and an opptide is co-injection	AVAILABILITY STATI AVAILABILITY STATI Ic Release; Distril Y NOTES Y NOTES ts, including depu- jinex to angiogeni ted. Using NMR s	EMENT bution Unlimited in which inhibits angic anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir equires the presen e also produced mu	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect ultiple variants	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 14. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe anastellin and an peptide is co-injecting n key nucleic aci	AVAILABILITY STATI AVAILABILITY STATI IIC Release; Distril Y NOTES Y NOTES Carrier anginex also has cts, including depu- jinex to angiogeni ted. Using NMR s I positions which a	EMENT bution Unlimited anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir equires the presen e also produced mu nastellin. These va	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect ultiple variants ariants can hel	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally simund to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-function
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe anastellin and an oeptide is co-inject n key nucleic acid relationship of an	AVAILABILITY STATI AVAILABILITY STATI IIC Release; Distril Y NOTES Y NOTES Y NOTES yment of fibronect anginex also has cts, including depu- ginex to angiogeni ted. Using NMR s J positions which a giogenesis inhibito	EMENT bution Unlimited in which inhibits angic anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir equires the presen e also produced mu nastellin. These va	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect ultiple variants ariants can hel	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-functio
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe anastellin and an opptide is co-inject n key nucleic acid relationship of an	AVAILABILITY STATI AVAILABILITY STATI Ic Release; Distril Y NOTES Y NOTES Inex to angiogeni ted. Using NMR s I positions which a giogenesis inhibito	EMENT bution Unlimited in which inhibits anglo anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir requires the presen e also produced mu nastellin. These va	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect ultiple variants ariants can hel	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-functic
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 14. ABSTRACT Anastellin is a fragon synthetic peptide biochemical aspe anastellin and and peptide is co-inject n key nucleic acid relationship of an	AVAILABILITY STATI AVAILABILITY STATI IIC Release; Distril Y NOTES Y NOTES Cartes anginex also has cts, including depu- jinex to angiogeni ted. Using NMR s J positions which a giogenesis inhibito	EMENT bution Unlimited anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir requires the presen e also produced mi nastellin. These va	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect ultiple variants ariants can hel	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-functio
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT Anastellin is a fra- synthetic peptide biochemical aspe anastellin and an oeptide is co-injed n key nucleic acid relationship of an	AVAILABILITY STATI AVAILABILITY STATI lic Release; Distril Y NOTES Y NOTES yment of fibronect anginex also has cts, including depu- ginex to angiogeni ted. Using NMR s J positions which a giogenesis inhibito	EMENT bution Unlimited in which inhibits angle anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir requires the presen e also produced mu nastellin. These va	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect ultiple variants ariants can hel	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-functic
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe anastellin and an opptide is co-inject n key nucleic acid relationship of an	AVAILABILITY STATI AVAILABILITY STATI Ic Release; Distril Y NOTES Y NOTES yinex to angiogeni ted. Using NMR s J positions which a giogenesis inhibito	EMENT bution Unlimited in which inhibits anglo anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir requires the presen e also produced mu nastellin. These va	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect ultiple variants ariants can hel	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-functio
2. DISTRIBUTION 7 Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe anastellin and any beptide is co-inject n key nucleic acid relationship of an 15. SUBJECT TERM drug targeting, ar	and Research and N land 21702-5012 AVAILABILITY STATI lic Release; Distril Y NOTES yment of fibronect anginex also has cts, including depu- ginex to angiogenisted. Using NMR s 1 positions which a giogenesis inhibito	EMENT bution Unlimited anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir equires the presen e also produced mu nastellin. These va	wth, and meta nd has been for n to be active <i>ii</i> ce of fibronect ultiple variants ariants can hel	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally simund to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-functio
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT 4. ABSTRACT 4. ABSTRACT 4. ABSTRACT 5. SUBJECT TERM 4. ABSTRACT 5. SUBJECT TERM 4. ABSTRACT 5. SUBJECT TERM	and Research and N land 21702-5012 AVAILABILITY STATI lic Release; Distril Y NOTES yment of fibronect anginex also has cts, including depu- ginex to angiogeni ted. Using NMR s 1 positions which a giogenesis inhibito	EMENT bution Unlimited in which inhibits anglo anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir requires the presen e also produced mu nastellin. These va	wth, and meta nd has been for n to be active <i>i</i> ce of fibronect ultiple variants ariants can help	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-functio
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT 4. ABSTRACT Anastellin is a fragon synthetic peptide biochemical aspen anastellin and any peptide is co-inject n key nucleic acid relationship of any 15. SUBJECT TERM drug targeting, ar 16. SECURITY CLAS	AVAILABILITY STATI AVAILABILITY STATI lic Release; Distril Y NOTES Y NOTES yment of fibronect anginex also has cts, including dep ginex to angiogeni ted. Using NMR s d positions which a giogenesis inhibito SiFICATION OF:	EMENT bution Unlimited in which inhibits angle anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir equires the presen e also produced mu nastellin. These va	11. 11. 11. 11. 11. 11. 11. 11. 11. 11.	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-function
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT Anastellin is a frag synthetic peptide biochemical aspe anastellin and any beptide is co-inject n key nucleic acid relationship of an 15. SUBJECT TERM drug targeting, ar 16. SECURITY CLAS	AVAILABILITY STATI AVAILABILITY STATI IIC Release; Distril Y NOTES Y NOTES	EMENT bution Unlimited in which inhibits angic anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir equires the presen e also produced mi nastellin. These va	11. 11. 11. 11. 11. 12. 12. 12. 13. 14. 15. 15. 15. 15. 15. 15. 15. 15. 15. 15	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally sim und to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-function p elucidate the structure-function
2. DISTRIBUTION / Approved for Pub 3. SUPPLEMENTAR 4. ABSTRACT 4. ABSTRACT 4. ABSTRACT 4. ABSTRACT 5. SUPPLEMENTAR 5. SUBJECT TERM 6. SECURITY CLAS 6. REPORT U	AVAILABILITY STATI AVAILABILITY STATI lic Release; Distril Y NOTES Y NOTES	EMENT bution Unlimited in which inhibits angic anti-angiogenic and a endence on circulating ic blood vessels also r structural data we hav alter the structure of a ors.	ogenesis, tumor gro nti-tumor effects an g plasma fibronectir equires the presen e also produced mu nastellin. These va	wth, and meta nd has been for n to be active <i>ii</i> ce of fibronect ultiple variants ariants can help 18. NUMBER OF PAGES	SPONSOR/MONITOR'S REPORT NUMBER(S) stasis <i>in vivo</i> . A structurally simund to resemble anastellin in se <i>n vivo</i> . The specific homing of in and is inhibited when an RGI of anastellin that contain mutat p elucidate the structure-function p elucidate the structure-function 19a. NAME OF RESPONSIBLE PE USAMRMC 19b. TELEPHONE NUMBER (includicode)

# TABLE OF CONTENTS

COVER	1
SF298	2
TABLE OF CONTENTS	3
INTRODUCTION	4
BODY	5
RESEARCH AND TRAINING ENVIRONMENT	8
KEY RESEARCH ACCOMPLISHMENTS	9
REPORTABLE OUTCOMES	9
CONCLUSIONS	9
REFERENCES	10

### INTRODUCTION

Previous work in our laboratory developed anastellin, which is a 10 kDa fragment of the first type III repeat of fibronectin. It has been shown that anastellin inhibits angiogenesis, tumor growth and metastasis *in vivo* [1-3]. The structure is a  $\beta$ -sheet with an exposed hydrophobic area in the middle [4]. Anastellin polymerizes with fibronectin *in vitro* [1] and requires circulating plasma fibronectin to be anti-angiogenic *in vivo* [5]. Other angiogenesis inhibitors, antithrombin and endostatin, also have been shown to depend on fibronectin and vitronectin to be active *in vivo* [5].

The Beta sheet structural motif is common among angiogenesis inhibitors. Recently, a synthetic 33-amino acid peptide, anginex, was modeled to reproduce the  $\beta$ -sheet structure of anti-angiogenic proteins. Anginex inhibits angiogenesis and tumor growth [6-8], and the bioactive form of anginex has a  $\beta$ -sheet structure [7].

We have found that anginex shares many of the functional properties of anastellin. It has been shown that anginex, similar to anastellin, binds to fibronectin and initiates its polymerization. Moreover, anginex is inactive in mice that lack plasma fibronectin. We have also found that anginex- and anastellin-fibronectin complexes home to angiogenic blood vessels *in vivo*. Anginex and anastellin are both dependent on fibronectin to home to angiogenic blood vessels *in vivo* and are inhibited by an Arg-Gly-Asp peptide.

#### BODY

In order to test the hypothesis that it is the RGD sequence of fibronectin that functions as a homing sequence for the anti-angiogenic peptide-fibronectin complexes we added an N-terminal cysteine residue to anastellin and conjugated fluorescein molecules to it using maleimide linkage chemistry. When mixed with fibronectin, anastellin induces the formation of fibronectin fibrils [1]. To check for activity, the conjugated anastellin was mixed with fibronectin and allowed to form fibrils. Turbidity was measured at an optical density of 590 nm to quantify the polymerization. 'An inactive repeat of fibronectin, III-11C, was used as a negative control. The N-terminal fluorescein conjugated anastellin was able to form fibrils when mixed with 0.5 mg/ml of fibronectin in PBS (Fig 1).

Fluorescein-conjugated anastellin and aginex were injected into wild-type and fibronectin knock-out mice that had been implanted with matrigel plugs for 8 days to determine if fibronectin is necessary for the specific homing of these anti-angiogenic peptides (Fig 2). Homing of anastellin and anginex was restored in the fibronectin null mice when 0.5 mg of fibronectin was also injected into the mice (Fig 2 D and H). Our hypothesis that the homing of the peptide-fibronectin complex is due to the RGD sequence of fibronectin was directly tested by co-injecting an RGD peptide with fluorescein-conjugated anastellin and anginex to determine if the homing to angiogenic vessels is blocked. Figure 3 shows that the RGD peptide blocks specific homing by anastellin and aginex to angiogenic vessels *in vivo*.

A  $\beta$ -sheet structural motif is shared by inhibitors of angiogenesis. Variants of anastellin were designed using the NMR structural data [4] and contain specific mutations in the sequence which disrupt the structure of anastellin. The polymerization activity of fibronectin by the anastellin variants and its affect on anti-angiogenic activity and homing *in vivo* will be studied.



**Fig 1.** Activity of fluorescein conjugated anastellin. Peptides at a concentration of 1.5 mg/ml were mixed with 0.5 mg/ml of fibronectin and polymerization was monitered by measuring optical density at 590 nm. (III-1C-Anastellin, III-11C-Inactive repeat of fibronectin, III-11CNA-anastellin with an N-terminal cysteine, and \*III-1CNA-FITC conjugated to the N-terminal cysteine of anastellin).



**Fig 2.** Anastellin and anginexhometo angiogenic vasculature *in vivo*. Normal or plasma fibronectindeficient mice implanted with Matrigel plugs 8 days earlier were i.v. injected with fluorescein-labeled anastellin (750 $\mu$ g; *A*–*D* and *I*–*L*) or anginex (250 $\mu$ g; *E*–*H* and *M*–*P*), and the mice were killed 2 h later. Endothelial cells in the plugs and in various tissues were visualized with anti-CD31 staining. Yellow reveals colocalization of the injected fluorescent protein (green) and endothelium (red). Nuclei were counterstained with DAPI (blue). Anastellin and anginex fluorescence is observed in the plugs from wildtype mice (*A* and *E*). The vessels in the plugs of pFN<sup>-/-</sup> mice showed no significant anastellin (*B*) or anginex (*F*) fluorescence, whereas the plugs of the pFN<sup>-/-</sup> mice restored the homing of anastellin (*D*) and anginex (*H*) to the plugs. No anastellin or anginex fluorescence was detected in the s.c. tissue (the site of the Matrigel plug implantation; *I* and *M*), the heart (*J* and *N*), or the brain (*K* and *O*). Faint green fluorescence was present in the liver (*L* and *P*). (Original magnification: 400X.)



**Fig 3.** The homing of anastellin and anginex to angiogenic vasculature is inhibited by an RGD-containing peptide. Mice bearing Matrigel plugs were i.v. injected with fluorescein-labeled anastellin (A-C) or anginex (D-F) as in Fig. 2 together with PBS (A and D), 10mgof GRGDSP (B and E), or an equal molar amount of an unrelated peptide (C and F). Little or no fluorescence is observed in the Matrigel plugs of mice coinjected with the RGD-containing peptide.

### **RESEARCH TRAINING AND ENVIRONMENT**

I have benefited greatly from doing my pre-doctoral research at the Burnham Institute for Medical Research in the lab of Dr. Erkki Ruoslahti. There is a weekly seminar series with invited speakers on the campus and the institute is within a two-mile radius of The Scripps Research Institute, The Salk Institute and UCSD which also each host numerous seminars on a wide range of topics.

The lab also has daily group meetings in which members of the lab present papers for discussion and also present their ongoing progress on their projects. Outside speakers are also invited to the meetings once a week to present their research and introduce different techniques to the lab. Guidance is also given through individual discussions to give suggestions on the direction of projects and future experiments.

## **KEY RESEARCH ACCOMPLISHMENTS**

- Fluorescein was conjugated to an N-terminal cysteine of anastellin, which is still active
- Fibronectin is necessary for the specific homing of anastellin and anginex to angiogenic vessels *in vivo*
- Homing of anastellin and anginex to angiogenic vessels is blocked by the coinjection of an RGD peptide
- Variants of anastellin containing mutations at key sites affecting the structure of anastellin have been produced

#### **REPORTABLE OUTCOMES**

Akerman, M.E., Pilch, J., Peters, D., Ruoslahti, E. (2005) Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. PNAS, 102:2040-2045.

#### CONCLUSIONS

We have made significant progress toward understanding the mechanism of anastellin and anginex *in vivo*. The original goal of this project was to target anastellin to specific vascular sites *in vivo* by fusing anastellin with homing peptides that home to the vasculature of breast cancers. However, this did not improve the efficacy of anastellin. Anastellin and anginex appear to be naturally targeted to angiogenic vasculature *in vivo* by co-aggregating with fibronectin and utilizing the RGD-sequence of fibronectin to home to angiogenic vasculature. The presence of fibronectin is necessary for the homing of anastellin and anginex to angiogenic vessels *in vivo* and is specifically blocked by the co-injection of an RGD peptide. Variants of anastellin have also been developed using the NMR structural data which contain point mutations affecting the structure of the peptide. The can be studied to further clarify the structure-function relationship of inhibitors of angiogenesis.

#### REFERENCES

- 1. Morla, A., Z. Zhang, and E. Ruoslahti. *Nature*, 1994. 367(6459): p. 193-6.
- 2. Pasqualini, R., et al. Nat Med, 1996. 2(11): p. 1197-203.
- 3. Yi, M. and E. Ruoslahti. Proc Natl Acad Sci USA, 2001. 98(2): p. 620-4.
- 4. Briknarova, K., et al. J Mol Biol, 2003. 332(1): p. 205-15.
- 5. Yi, M., et al. Proc Natl Acad Sci USA, 2003. 100(20): p. 11435-8.
- 6. Griffioen, A.W., et al. Biochem J, 2001. 354(Pt 2): p. 233-42.
- 7. Dings, R.P., et al. Biochem J, 2003. 373(Pt 1): p. 281-8.
- 8. van der Schaft, D.W., *et al. Faseb J*, 2002. 16(14): p. 1991-3.